Difficulty: Medium
Average Score: 84%
Practice
The following drugs prolong the QT interval and/or cause torsades de pointes EXCEPT:
Correct answer
D
Rationale
In this question, the correct answer is option D) Tacrolimus. Tacrolimus is an immunosuppressant medication commonly used in organ transplant recipients. It does not prolong the QT interval or cause torsades de pointes, making it the exception among the listed drugs.
Erythromycin (option A) is a macrolide antibiotic known to prolong the QT interval and can lead to torsades de pointes. Pimozide (option B) is an antipsychotic medication that also prolongs the QT interval and can cause this life-threatening arrhythmia. Disopyramide (option C) is an antiarrhythmic drug that can prolong the QT interval and increase the risk of torsades de pointes.
Educationally, understanding the potential cardiac side effects of medications is crucial for healthcare professionals, especially those working in cardiology, critical care, or primary care settings. Recognizing drugs that can prolong the QT interval and cause torsades de pointes is vital for patient safety and effective medication management. By knowing which drugs to monitor closely and potentially avoid in patients with underlying cardiac conditions, healthcare providers can prevent serious adverse events and improve patient outcomes.
Erythromycin (option A) is a macrolide antibiotic known to prolong the QT interval and can lead to torsades de pointes. Pimozide (option B) is an antipsychotic medication that also prolongs the QT interval and can cause this life-threatening arrhythmia. Disopyramide (option C) is an antiarrhythmic drug that can prolong the QT interval and increase the risk of torsades de pointes.
Educationally, understanding the potential cardiac side effects of medications is crucial for healthcare professionals, especially those working in cardiology, critical care, or primary care settings. Recognizing drugs that can prolong the QT interval and cause torsades de pointes is vital for patient safety and effective medication management. By knowing which drugs to monitor closely and potentially avoid in patients with underlying cardiac conditions, healthcare providers can prevent serious adverse events and improve patient outcomes.